Welcome to our dedicated page for Maravai Lifesciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai Lifesciences Holdings stock.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a life sciences company that regularly issues news and updates related to its role as a global provider of life science reagents and services. This news page aggregates announcements about Maravai’s financial performance, strategic initiatives, collaborations, and leadership changes, giving investors and researchers a focused view of developments that affect the MRVI stock and the company’s operating outlook.
Maravai’s news flow often centers on quarterly financial results, where the company reports revenue, net loss, segment performance for Nucleic Acid Production and Biologics Safety Testing, and non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Loss. These releases typically include management commentary on trends in base business revenue, demand for nucleic acid products, and growth in biologics safety testing offerings such as host cell protein kits and MockV viral clearance kits.
In addition to earnings releases, Maravai publishes updates on organizational restructuring and cost reduction initiatives, including workforce reductions and efforts to align its cost structure with its current scale. The company also announces leadership transitions, such as the appointment of a new Chief Executive Officer and Chief Financial Officer, along with related governance and board changes documented in Form 8-K filings.
Another key area of MRVI news involves partnerships and agreements through Maravai’s TriLink BioTechnologies business. Recent announcements include license and supply agreements for TriLink’s CleanCap mRNA capping technology with partners that integrate this technology into RNA production platforms, as well as memoranda of understanding to collaborate on mRNA-based vaccine development and promote equitable access to vaccines in low- and middle-income countries.
Visitors to this page can review Maravai’s conference call and webcast notices, investor conference participation, and other corporate communications that provide context on the company’s strategic focus in nucleic acid technologies, mRNA tools, and biologics safety testing.
Maravai LifeSciences Holdings (MRVI) reported record financial results for Q2 2022, with revenue of $242.7 million, an 11% increase year-over-year. The Nucleic Acid Production segment saw a 17% revenue increase to $225.2 million. Net income reached $156.7 million, up 17% from the previous year. Noteworthy is the 42% growth in Nucleic Acid Production for the first half of 2022. The company signed a Cooperative Agreement with the Department of Defense for manufacturing expansion. Adjusted EBITDA for Q2 was $188.5 million, reflecting strong cash position for future growth.
Maravai LifeSciences (MRVI) will release its second quarter 2022 financial results post-market on August 4, 2022. A conference call will follow at 2:00 p.m. PT/5:00 p.m. ET, accessible via phone or webcast. The company specializes in life science products critical for drug therapy and vaccine development, supporting biotechnology and pharmaceutical sectors globally.
TriLink BioTechnologies, a subsidiary of Maravai LifeSciences (NASDAQ: MRVI), has appointed Dr. Kate Broderick as Senior Vice President of Research and Development. In this role, she will spearhead the company's R&D strategy and contribute to its growth as a key supplier of modified nucleic acids. Dr. Broderick brings over 15 years of experience from Inovio Pharmaceuticals, along with expertise in DNA technology, gene delivery, and vaccine development. Her leadership is expected to bolster TriLink's capabilities in supporting clients through clinical trials and product development.
Maravai LifeSciences (NASDAQ: MRVI) announced the appointment of Dr. Peter Leddy as Executive Vice President and Chief Administrative Officer. Dr. Leddy will lead global shared services functions, including Human Resources, Environmental, Social and Governance initiatives, and Diversity, Equity and Inclusion efforts. With over 30 years in the healthcare sector, his experience aims to foster long-term growth and enhance company culture. He previously consulted for Maravai and has held executive roles in various organizations. This strategic hire is expected to strengthen leadership as Maravai evolves in its market.
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), announced a Cooperative Agreement with the Army Contracting Command to enhance its domestic production capacity for crucial mRNA vaccine components. The Department of Defense will fund up to $39 million for the expansion in San Diego, California, aimed at increasing manufacturing of nucleoside triphosphates and CleanCap® capping reagents. This initiative will also prepare the U.S. for future pandemics, addressing heightened demand for nucleic acid products critical to COVID-19 vaccine development.
Maravai LifeSciences (NASDAQ: MRVI) is set to participate in several upcoming investor conferences. CFO Kevin Herde will engage in a fireside chat at the UBS Global Healthcare Conference on May 25, 2022, followed by a presentation at the William Blair Growth Conference on June 8, 2022. Additionally, Mr. Herde will participate in another fireside chat at the Goldman Sachs Global Healthcare Conference on June 14, 2022. Webcasts of these events will be available on the Maravai Investor Relations website, along with archived versions post-event.
Maravai LifeSciences Holdings reported strong financial results for Q1 2022, with record revenues of $244.3 million, a 65% year-over-year increase. The Nucleic Acid Production segment grew 80.5%, driven by a high demand for COVID-19 related CleanCap products. The company achieved a net income of $146.9 million, up 95% from the previous year, alongside an Adjusted EBITDA of $187 million. Maravai has raised its guidance for Adjusted EBITDA and Adjusted EPS for the full year 2022, reflecting optimism in ongoing therapeutic and vaccine developments beyond COVID-19.
Maravai LifeSciences, Inc. (NASDAQ: MRVI) will report its first quarter 2022 financial results on May 5, 2022, post-market. A conference call is scheduled for the same day at 2:00 PM PT. Investors can participate by calling (800) 806-5484 or (416) 340-2217, using the passcode 7725912#. A replay will be available for 72 hours at (800) 408-3053 or (905) 694-9451, along with a webcast on the Maravai website.
Maravai specializes in life science reagents and services, supporting drug therapies, diagnostics, and vaccine development for leading global biopharmaceutical companies.
Bio-Techne Corporation (NASDAQ: TECH) and Cygnus Technologies, part of Maravai LifeSciences (NASDAQ: MRVI), have launched the Simple Plex™ HEK 293 HCP 3G assay for automated impurity testing on the Ella™ platform. This innovative assay enhances viral production workflows by accurately quantifying host cell protein (HCP) impurities in a rapid, 90-minute process. It promises improved consistency and reduced variability compared to traditional methods, leveraging Cygnus's established HCP detection technology. The collaboration aims to support the growing cell and gene therapy market.
Maravai LifeSciences, Inc. (MRVI) announced its participation in key investor conferences in March 2022. CFO Kevin Herde will engage in a fireside chat at the Barclays Global Healthcare Conference on March 15 at 6:30 a.m. PT. Additionally, COO Brian Neel will join a panel discussion on mRNA at the KeyBanc Life Sciences & MedTech Investor Forum on March 23, followed by another fireside chat led by Herde at 12:00 p.m. PT. Webcasts of these events will be accessible on the Maravai Investor Relations website, with archived versions available post-event.